Adults 40 to 80, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Six-Minute Walk Test DistancePrimary· Change Six-Minute Walk Test Distance from Baseline to 4 Weeks
Total distance walked in 6 minutes in meters
Group
Value
95% CI
High-Intensity Interval Training
27
6 – 48
Moderate-Intensity Aerobic Training
12
-9 – 33
Six-Minute Walk Test DistancePrimary· Change Six-Minute Walk Test Distance from Baseline to 8 Weeks
Total distance walked in 6 minutes in meters
Group
Value
95% CI
High-Intensity Interval Training
58
39 – 76
Moderate-Intensity Aerobic Training
29
9 – 48
Six-Minute Walk Test DistancePrimary· Change Six-Minute Walk Test Distance from Baseline to 12 Weeks
Total distance walked in 6 minutes in meters
Group
Value
95% CI
High-Intensity Interval Training
71
49 – 94
Moderate-Intensity Aerobic Training
27
3 – 50
Comfortable Gait SpeedSecondary· Change from Baseline to 4 Weeks
From 10-meter walk test, in meters per second
Group
Value
95% CI
High-Intensity Interval Training
0.11
0.06 – 0.15
Moderate-Intensity Aerobic Training
0.02
-0.02 – 0.07
Comfortable Gait SpeedSecondary· Change from Baseline to 8 Weeks
From 10-meter walk test, in meters per second
Group
Value
95% CI
High-Intensity Interval Training
0.14
0.08 – 0.20
Moderate-Intensity Aerobic Training
0.06
0.00 – 0.12
Comfortable Gait SpeedSecondary· Change from Baseline to 12 Weeks
From 10-meter walk test, in meters per second
Group
Value
95% CI
High-Intensity Interval Training
0.19
0.13 – 0.25
Moderate-Intensity Aerobic Training
0.06
0.00 – 0.12
Fast Gait SpeedSecondary· Change from Baseline to 4 Weeks
From 10-meter walk test, in meters per second
Group
Value
95% CI
High-Intensity Interval Training
0.22
0.16 – 0.28
Moderate-Intensity Aerobic Training
0.01
-0.05 – 0.07
Fast Gait SpeedSecondary· Change from Baseline to 8 Weeks
From 10-meter walk test, in meters per second
Group
Value
95% CI
High-Intensity Interval Training
0.24
0.17 – 0.32
Moderate-Intensity Aerobic Training
0.09
0.01 – 0.17
Fast Gait SpeedSecondary· Change from Baseline to 12 Weeks
From 10-meter walk test, in meters per second
Group
Value
95% CI
High-Intensity Interval Training
0.28
0.19 – 0.37
Moderate-Intensity Aerobic Training
0.09
-0.01 – 0.18
Aerobic FitnessSecondary· Change from Baseline to 4 Weeks
Oxygen consumption rate at ventilatory threshold during treadmill graded exercise test, in milliliters per kilogram body mass per minute
Group
Value
95% CI
High-Intensity Interval Training
1.3
0.4 – 2.2
Moderate-Intensity Aerobic Training
0.4
-0.5 – 1.3
Aerobic FitnessSecondary· Change from Baseline to 8 Weeks
Oxygen consumption rate at ventilatory threshold during treadmill graded exercise test, in milliliters per kilogram body mass per minute
Group
Value
95% CI
High-Intensity Interval Training
2.0
0.7 – 3.3
Moderate-Intensity Aerobic Training
1.7
0.3 – 3.1
Aerobic FitnessSecondary· Change from Baseline to 12 Weeks
Oxygen consumption rate at ventilatory threshold during treadmill graded exercise test, in milliliters per kilogram body mass per minute
Group
Value
95% CI
High-Intensity Interval Training
1.9
0.4 – 3.4
Moderate-Intensity Aerobic Training
1.4
-0.2 – 3.0
Adverse events — posted to ClinicalTrials.gov
Time frame: Duration of participant enrollment post-randomization, which was approximately 4 months for participants who completed the study.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The objective of this study is to determine the optimal training intensity and the minimum training duration needed to maximize immediate improvements in walking capacity in chronic stroke. A single-blind, phase II, 3-site randomized controlled trial has been planned. Fifty persons \>6 months post stroke will randomize to either moderate-intensity aerobic locomotor training or high-intensity interval locomotor training; each for 45 minutes, 3x/week for up to 36 total sessions over approximately 12 weeks. Clinical measures of walking function, aerobic fitness, daily walking activity and quality of life will be assessed at baseline (PRE) and after 4, 8 and 12 weeks of training (POST-4WK, POST-8WK, POST-12WK).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke
· recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment
· NA
· recruiting
NCT07356011 — Exoskeleton for Balance
· NA
· recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in
· NA
· recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients
· NA
· recruiting
Other University of Cincinnati trials
Trials by the same sponsor.
NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
· Phase 1
· not yet recruiting
NCT07528638 — Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND)
· NA
· not yet recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment
· NA
· recruiting
NCT07447895 — Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies
· NA
· not yet recruiting
NCT07231588 — Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation
· EARLY_PHASE1
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cincinnati
Last refreshed: 26 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03760016.